Key points are not available for this paper at this time.
Most of the clinical and economic burden of Respiratory Syncytial Virus (RSV) in pediatric populations is concentrated among infants aged 44,000 hospitalizations annually in infants in France, representing a total cost exceeding €130 million, annually. This study highlighted the impact of transitional months in RSV circulation. It also emphasized that the youngest patients (< 3 months) represent nearly 50% of the economic burden. To reduce RSV disease burden, it is essential to protect infants against RSV both inside and outside the classically defined epidemic season, especially in the first months of life. Not applicable.
Cohen et al. (Thu,) studied this question.